Fujimycin Interactions
Formal topical drug interaction studies with PROTOPIC Ointment have not been conducted. Based on its minimal
extent of absorption, interactions of PROTOPIC Ointment with systemically administered drugs are unlikely to occur
but cannot be ruled out. The concomitant administration of known CYP3A4 inhibitors in patients with widespread and/or
erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole,
ketoconazole, fluconazole, calcium channel blockers and cimetidine.
Fujimycin Contraindications
PROTOPIC Ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or
any other component of the preparation.
Additional information about Fujimycin
Fujimycin Indication: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Mechanism Of Action: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Fujimycin also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Tacrolimus
Synonyms: FK5; Tacarolimus; FK-506; K506
Where to order Tacrolimus (and Fujimycin analogs) online:
Drug Category: Immunosuppressive Agents
Drug Type: Small Molecule; Approved; Investigational
Other Brand Names containing Tacrolimus: Prograf;
Protopic;
Fujimycin;
Absorption: 20% bioavailability; less after eating food rich in fat
Toxicity (Overdose): Side effects can be severe and include blurred vision, liver and kidney problems (it is nephrotoxic), seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, itching, insomnia, confusion. LD
50=134-194 mg/kg (rat).
Protein Binding: 75-99%
Biotransformation: Hepatic, extensive, primarily by CYP3A4. The major metabolite identified in incubations with human liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported to have the same activity as tacrolimus.
Half Life: 11.3 hours (range from 3.5 to 40.6 hours)
Dosage Forms of Fujimycin: Solution Intravenous
Ointment Topical
Capsule Oral
Chemical IUPAC Name: [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3- [2-(4-hydroxy-3-methoxycyclohexyl) -1-methylethenyl]-14, 16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15, 19-epoxy-3H-pyrido[2,1-c][1,4] oxaazacyclotricosine-1,7,20, 21(4H,23H)-tetrone, monohydrate
Chemical Formula: C44H69NO12
Tacrolimus on Wikipedia: http://en.wikipedia.org/wiki/Tacrolimus
Organisms Affected: Humans and other mammals